WO2022147338A1 - Monoclonal antibody against human mac-1 and uses thereof - Google Patents

Monoclonal antibody against human mac-1 and uses thereof Download PDF

Info

Publication number
WO2022147338A1
WO2022147338A1 PCT/US2021/065802 US2021065802W WO2022147338A1 WO 2022147338 A1 WO2022147338 A1 WO 2022147338A1 US 2021065802 W US2021065802 W US 2021065802W WO 2022147338 A1 WO2022147338 A1 WO 2022147338A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
mac
antibody
cdr
cdr sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/065802
Other languages
French (fr)
Inventor
Frank Wen-Chi LEE
Yen-Ta Lu
Chia-Ming Chang
Ping-Yen Huang
I-Fang Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendo Biotechnology Inc Taiwan
Original Assignee
Ascendo Biotechnology Inc Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendo Biotechnology Inc Taiwan filed Critical Ascendo Biotechnology Inc Taiwan
Priority to CN202180094281.XA priority Critical patent/CN116963772A/en
Priority to JP2023540621A priority patent/JP2024501884A/en
Priority to BR112023013052A priority patent/BR112023013052A2/en
Priority to CA3203552A priority patent/CA3203552A1/en
Priority to EP21916546.1A priority patent/EP4271413A4/en
Priority to US18/259,958 priority patent/US20240084017A1/en
Priority to AU2021413899A priority patent/AU2021413899A1/en
Priority to KR1020237025748A priority patent/KR20230140448A/en
Priority to TW111119536A priority patent/TWI869677B/en
Priority to TW113121565A priority patent/TWI911761B/en
Publication of WO2022147338A1 publication Critical patent/WO2022147338A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • Macrophage-1 antigen (Mac-1, integrin aM02) is mainly expressed on the surface of innate immune cells (including monocytes, neutrophils, NK cells, etc.).
  • Mac-1 is a heterodimeric glycoprotein comprising non-covalently linked integrin aM (CD 11b, CR3A, ITGAM) and integrin 02 (CD18, ITGB2).
  • CD1 lb is a transmembrane protein with alarge extracellular domain and a short cytoplasmic tail. Its extracellular domain comprises an I domain, a 0-propeller domain, a thigh domain, a calf-1 domain, and a calf-2 domain.
  • the I domain of CDllb has around 179 amino acids inserting into the 0-propeller domain. This I domain is responsible for binding to promiscuous ligands (e.g., iC3b, fibrinogen, ICAM-1, CD40L, etc.) and participates in cell adhesion, migration, chemotaxis, and phagocytosis, and regulates inflammatory responses of innate immune cells.
  • promiscuous ligands e.g., iC3b, fibrinogen, ICAM-1, CD40L, etc.
  • Mac-1 exists in distinct conformations with different ligand binding affinities.
  • CD1 lb and CD18 are bent in a V shape with the I-domain close to the membrane to form an inactive Mac-1 (low affinity).
  • Inside-out signaling changes the Mac-1 to an open conformation, extending the I domain away from the membrane for optimal ligand binding.
  • One epitope located on the I-EGF2 of CD 18 is hidden in the bent conformation (inactive or closed state); this epitope becomes exposed and can be recognized by a monoclonal antibody (KIM127) in the extended or open state (J. Immunol. 2001; 166: 5629-5637).
  • This conformational change also results in the rearrangement of the I domain site such that it becomes a high affinity site for ligand binding and forms an epitope for mAb m24 binding (Proc. Natl. Acad. Sci. USA. 2004; 101: 2333-2338).
  • Such conformational changes accompanying ligand binding affinity changes are tied to Mac-1 functions.
  • Embodiments of the invention relate to antibodies that can bind specifically to Mac-1 and modulate immune cell functions. These antibodies may be used to treat various Mac-1 associated diseases or conditions, such as infectious diseases or cancers.
  • One aspect of the invention relates to antibodies against human Mac-1.
  • An antibody against human Mac-1 in accordance with one embodiment of the invention comprises a lightchain variable region sequence and a heavy -chain variable region sequence selected from SEQ ID NO:1 through SEQ ID NO: 158 shown in Table I.
  • One aspect of the invention relates to methods for treating a disorder associate with Mac-1.
  • a method in accordance with one embodiment of the invention comprises administering to a subject in need thereof an effective amount of an antibody of the invention.
  • the disorder is an acute or chronic inflammation.
  • the disorder may be an infection or a cancer.
  • FIG. 1 shows the two conformations of Mac-1 and their epitopes for activationsensitive mAbs.
  • FIG. 2 shows results of characterization of HEK293/Mac-1 using various antibodies.
  • HEK293 cells were incubated in PBS (Mock) or PBS/MnCh (Mn 2+ ). Bindings of isotype control IgG, a CD1 lb specific mAb (clone ICRF44), a CD18 specific mAb (clone 6.7), or P2 activationdependent mAbs (KIM127 and m24) were detected using flow cytometry.
  • FIG. 3A shows that representative anti-Mac-1 antibodies of the invention (DF3M-5, H4L2, m2396, 24G05, and 28E07-HH) predominantly bind to myeloid immune cells (monocytes and neutrophils). Other antibodies of the invention show similar properties.
  • FIG. 3B shows that clones m2396, DF3M-5, and 24G05 bind to mouse Mac-1 expressing cell line Raw264.7.
  • FIG. 4 shows examples of anti-Mac-1 antibodies that can modulate conformational changes of Mac-1 under PBS (Mock) or PBS/MnCh (Mn 2+ ) conditions.
  • FIG. 5 shows that anti -Mac- 1 antibody treatments can modulate TLR4 agonist- induced Thl/Th2 cytokines responses in mice in vivo. Data are shown as the means ⁇ SEM (4 mice per group).
  • FIG. 6 shows that anti-Mac-1 antibodies reduce tumor growths in A549 human lung tumor bearing humanized NOG-EXL mouse model in vivo. Data are shown as the means ⁇ SEM (10 mice per group).
  • FIG. 7A shows that anti-Mac-1 antibody enhanced the expression of functional markers in myeloid cells isolated from HIV patients.
  • FIG. 7B shows that anti -Mac- 1 antibody reduced the virus load in PBMCs from HIV patients.
  • Embodiments of the invention relate to antibodies that can bind specifically to Mac-1 and modulate immune cell functions. These antibodies may be used to treat various Mac-1 associated diseases or conditions, such as infectious diseases or cancers.
  • the antibodies and reagents used for flow cytometry are KIM 127 (hybridoma from ATCC), m24-PE (BioLegend), anti-CDl lb-APC (clone ICRF44, BioLegend), anti-CD18-APC (clone 6.7, BD), BSA (BioShop), Rat IgGlK-APC (BioLegend), and Rat IgGlK-PE (BioLegend).
  • the KIM127 antibody and BSA were conjugated with CF647, i.e., labeled with CF647 labeling kit (CF Dye & Biotin SE Protein Labeling Kits, Biotium).
  • HEK293 cells Stable transfection of human integrin Mac-1 in HEK293 cells (BCRC) was performed using jetP RIME® (PolyPlus) transfection protocols. Briefly, HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Coming), supplemented with 10% heat- inactivated fetal bovine serum (Gibco) and 50 lU/mL penicillin and streptomycin (Coming) at 37 °C. The cells were seeded at 8 x 10 5 cells/well on a 6-well plate (Coster).
  • DMEM Dulbecco
  • DMEM Modified Eagle’s Medium
  • Gibco heat- inactivated fetal bovine serum
  • Coming penicillin and streptomycin
  • a mixture of the jetPRIME® reagent and 2 pg pcDN A3.1 /human CD18 expression plasmid carrying a hygromycin-resistance gene was added to the cells, and the cells were cultured for 24 hr.
  • the selection antibiotic, hygromycin B (InvivoGen) was added at a concentration of 200 pg/ml, and half of the culture media containing the antibiotic were changed every 2 to 3 days.
  • the CD18-expression cells were collected using the Cell Sorter (SH800Z, SONY) to pick up CD18-high expression cells and seeded at single cell/well and 5000 cells/well on a24-well plate (Coster) and a 6-well plate.
  • the selection antibiotics 1 mg/ml G418 (InvivoGen) and 200 pg/ml Hygromycin B, were added, and the medium containing selection antibiotics was changed every 2 to 3 days.
  • the Mac-1 expression was measured with anti-human CDllb-APC (clone ICRF44, BioLegend) and anti-hCD18-APC by flow cytometry. The stable clone 1-4 was picked up.
  • the HEK293/Mac-1 cells (clonel-4) were counted and washed twice with staining buffer (PBS containing 1% FBS, and 0.1% sodium azide). Cells were adjusted at a concentration of 1x10 5 cells/ml in staining buffer and treated with/without 0.25 mM MnCh (Sigma). Cells were treated with anti -Mac- 1 antibodies and fluorescent conjugated anti -human IgG4 antibodies and incubated for 15 mins. After washing with the staining buffer, the cells were analyzed by flow cytometry.
  • staining buffer PBS containing 1% FBS, and 0.1% sodium azide
  • these cells were treated with the antibodies (ICRF44, KIM127, m24, or isotype control) in the presence or absence lOpg/ml anti-Mac-1 antibodies. The cells were then incubated at 37 °C for 30 min. After washing with the staining buffer, the cells were analyzed by flow cytometry.
  • the antibodies ICRF44, KIM127, m24, or isotype control
  • Murine Thl and Th2 cytokines in the serum were detected by ProcartaPlex MS (Thermo Fisher Scientific) according to the manufacturer instructions.
  • Human umbilical cord blood derived CD34+ cells were transplanted into NOG-EXL mice via the tail vein. About 10 weeks after transplantation, peripheral blood were collected from the humanized NOG-EXL animals under anesthesia and used for FACS analysis. The types, proportions, fluorescence intensities, and absolute counts of immune cells (T cells, B cells, dendritic cells, and monocyte cells) were analyzed. When the average hCD45 + % > 15%, hCD3 + of hCD45 + % > 3%, and hCD14 + of hCD45 + % > 5%, the humanized NOG-EXL animals were used for the anti -cancer study.
  • A549 cells were cultured in a 37 °C incubator containing 5% CO2 with 10% FBS in F-12K medium. The cells were sub-cultured within 10 passages before being inoculated into mice. A549 cells (5xl0 6 cells) were mixed with Matrigel (v/v 1:1) in a volume of 200 pl immediately before injection subcutaneously. Before inoculation, mice were anesthetized with 2-5% isoflurane.
  • tumor-bearing animals were grouped into 3 groups based on the frequency of macrophage in human CD45 + cells, the frequency of CD3 + cell in human CD45 + cells, and tumor volumes, each group contains 10 mice.
  • the day of grouping was denoted as day 0. Mice were treated on day 0.
  • PBMC Peripheral blood mononuclear cells
  • Intracellular HIV virus detection- 2 long-terminal repeat (LTR)- DNA circles quantitation [0030] DNA of 3 day-cultured PBMC (3xl0 6 cells/well in a 24-well culture plate) treated with/without PMA (lOOng/ml) and ionomycin (1 pg/ml) in the presence of human IgG4 antibody (BioLegend) or Anti-Mac-1 antibody (H4L2, 10 pg/ml) was extracted with QIAamp DNA Blood Mini Kit (Qiagen, MD, USA) and DNA were eluted by 50pl nuclease-free water. Digital PCR was performed with the QX100TM Droplet DigitalTM PCR platform (Bio-Rad, Hercules, California).
  • the ddPCR mix was made by adding 1-5 pl of sample to 10 pl 2x ddPCRTM supermix for probes (Bio-Rad), Ipl EcoR, 500 nM of primers, and 250 nM of probe in a final volume of 20 pl.
  • the mix was placed in an 8-channel cartridge, 70 pl of droplet generating oil (Bio-Rad) was added and droplets were generated in the QX100TM droplet generator (Bio-Rad). Droplet in oil suspensions were transferred to an ddPCR 96-well plate (Bio-Rad) and PCR was performed in the T100TM Thermal Cycler (Bio-Rad).
  • DdPCR amplification reactions consisted of an initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec denaturation and 60°C for 60 sec annealing/elongation temperature, and enzyme deactivation at 98°C for 10 min.
  • the ramping rate of each step is 2°C/sec.
  • the sequences of primer pairs are listed in Table VI.
  • Results were compared by Fisher’s exact test for categorical variables and paired t test or unpaired t test for continuous variables as appropriate. Data are reported as the mean ⁇ SEM. Statistical analysis was performed using Prism 9.0 software. Two-sided tests were used, and a p-value of ⁇ 0.05 was considered statistically significant.
  • HEK293 cells which do not express endogenous Mac-1, were transfected with pcDN A3.1 /human CDl lb and pcDN A3.1 /human CD18 plasmids using liposome transfections. After G418 and hygromycin selections, we obtained several single-cell clones stably expressing the human Mac-1 on the cell surface by FACS sorting using CD18-specific mAb (clone 6.7) and CDllb specific mAb (clone ICRF44). One clone, designated 1-4, was selected for all the examples presented in this description. Other clones show similar properties.
  • Anti-Mac- 1 antibodies selectively bind to the different states of Mac- 1 on HEK293/Mac-l cell surface
  • Anti-Mac- 1 antibodies predominantly bind to Mac-1 on the innate immune cell surface
  • the innate immune cells such as monocytes (CD14 + cells) and neutrophils (CD66b + cells) are the main cells that express Mac-1 on their cell surface. Some populations of B cells also expressed Mac-1 on their cell surface (Proc Natl Acad Sci U S A. 2008 Apr 1; 105(13):5195- 200).
  • the specificities of selective anti-Mac-1 antibodies were determined by flow cytometry using human whole blood. As shown in FIG. 3A, anti-Mac-1 antibodies in this example were able to bind to the innate immune cells (CD14 + and CD66b + cells) and small populations of B cells (CD19 + cells).
  • Anti -Mac- 1 antibodies induce a conformational change in Mac-1
  • m2396 and DF3M-5 treatments enhanced TLR4-induced Thl cytokines (such as IFN-y, IL-1 , and TNF-a) and slightly enhance TLR4-induced Th2 cytokines (such as IL-5 and IL-13) in the serum.
  • TLR4-induced Thl cytokines such as IFN-y, IL-1 , and TNF-a
  • Th2 cytokines such as IL-5 and IL-13
  • Anti-Mac- 1 antibody treatment reduces tumor growth
  • anti-cancer activities of the anti-Mac-1 antibodies of the invention were further evaluated in the treatment of A549 cancer model in female NOG- EXL humanized mice.
  • mice were randomized into 3 groups (Human IgG4, m2396, and 28E07-HH) and the treatments were started.
  • the mean tumor sizes of mice reached 172.59 mm 3 in Human IgG4 group, 132.51 mm 3 in m2396 group, and 109.88 mm 3 in 28E07-HH group on Day35 post grouping (FIG. 6).
  • FIG. 6 shows results from representative antibodies m2396 and 28E07-HH.
  • Other antibodies of the invention have similar properties.
  • the tumor growth inhibition (TGI) % of the m2396 group and 28E07-HH group were 23.59%, and 35.93%, respectively.
  • the TGI of the different groups at different time points were shown in Table V.
  • Anti-Mac- 1 antibody treatment reduced HIV viral load and reverses immunosuppressed phenotype of PBMC in HIV patients
  • PBMC isolated from fifteen latent HIV -infected patients were treated with anti -Mac- 1 antibodies for 3 days in vitro.
  • the anti-Mac-1 antibody H4L2 shown as a representative of anti-Mac-1 antibodies
  • FIG 7A the anti-Mac-1 antibody (H4L2 shown as a representative of anti-Mac-1 antibodies) significantly enhanced the expression of CD86 and MHC class II functional markers in myeloid cells of HIV patients.
  • DCs dendritic cells
  • HIV- 1 persists in the infected cells as a stable integrated genome and more labile unintegrated DNA, which includes linear, 1-LTR and 2-LTR circular DNA.
  • 2-LTR circle DNA although less abundant, is considered a surrogate marker for recent infection events and is currently used as a diagnostic tool.
  • C. Orlandi et al. “A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication,” J. Transl. Med. 18, 204 (2020). Doi: 10.1186/sl2967- 020-02368-y).
  • HIV virus DNA reservoir was quantified using the 2 long-terminal repeat (LTR) DNA circles as the marker. Because these fifteen HIV-1 infected patients were receiving regular highly active antiretroviral therapy (ART) treatments, only 3 of the 15 patients had detectable levels of the HIV DNA by the LTR assay. Nevertheless, declines in the HIV 2LTR DNA levels were observed in these 3 patients’ PBMC samples treated with the anti -Mac- 1 antibody or with the anti-Mac-1 antibody in combination with phorbol 12- myristate 13-acetate (PMA) and ionomycin (FIG. 7B).
  • ART highly active antiretroviral therapy
  • Anti-Mac- 1 antibody sequence clone 24F08 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24F09 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone: 24F11 Underline is a CDR sequence
  • Anti-Mac- 1 antibody sequence clone: 24F12 Underline is a CDR sequence
  • Anti-Mac-1 antibody sequence clone 24G01 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24G05 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24G07 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24G08 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24G09 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24G10 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24G11 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone 24G12 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone 24H01 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24H02 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 24H03 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 25A06 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 25A09 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 25A10 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 25B03 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 25B01 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3-10 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3-28 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3-30 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3-32 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4-16 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4-17 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4-25 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4-26 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4-42 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF3M-1 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF3M-2 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF3M-5 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3M-18 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF3M-19 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3M-30 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF3M-36 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF3M-42 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4M-1 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4M-3 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF4M-7-1 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone: DF4M-9 Underline is a CDR sequence
  • Anti-Mac-1 antibody sequence clone DF4M-11 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4M-17 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF4M-18 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4M-21 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4M-23 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF4M-30 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone DF4M-31 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF4M-45 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone 28A12 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone 27G04 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone: 27A04 Underline is a CDR sequence
  • Anti-Mac- 1 antibody sequence clone: 27A06 Underline is a CDR sequence
  • Anti-Mac- 1 antibody sequence clone: 28G06 Underline is a CDR sequence
  • Anti-Mac- 1 antibody sequence clone: 27B10 Underline is a CDR sequence
  • Anti-Mac- 1 antibody sequence clone 27D06 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28D06 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone 27E12 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone m2396 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone H4L2 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-HH (Underline is a CDR sequence)
  • Anti-Mac-1 antibody sequence clone 28E07-B1H (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-B2H (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-B3H (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-B4H (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-HB1 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-HB2 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone: 28E07-HB4 Underline is a CDR sequence
  • Anti-Mac- 1 antibody sequence clone 28E07-B1B1 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-B1B2 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-B2B1 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 28E07-B2B2 (Underline is a CDR sequence)
  • Table II The anti-Mac-1 antibodies selectively bind to different statuses of human Mac-1.
  • HEK293/Mac-1 cells (clonel-4) were incubated in PBS (Mock), or PBS/MnCh (Mn 2+ ).
  • Binding of isotype control IgG, the CDllb specific mAb (ICRF44), the CDllb activationsensing mAh (CBRM1/5), or the screened anti-Mac-1 antibody was detected using flow cytometry.
  • the anti-Mac-1 antibodies can serve as agonist to enhance the conformational change of Mac- 1.
  • HEK293/Mac-1 cells (clonel-4) were incubated with 10 pg/ml anti-Mac-1 antibodies under the PBS (Mock) condition. Binding of KIM127 or m24 was detected using flow cytometry.
  • the anti-Mac-1 antibody can serve as an antagonist to reduce the conformational change of Mac- 1.
  • HEK293/Mac-1 cells (clonel-4) were incubated with 10 Hg/ml anti-Mac-1 antibodies under the PBS/MnCh (Mn 2+ ) condition. Binding of KIMI 27 or m24 was detected using flow cytometry.
  • TGI Tumor growth inhibition
  • Anti-Mac- 1 antibody sequence clone 24H03 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone 25B03 (Underline is a CDR sequence)
  • Anti-Mac- 1 antibody sequence clone DF3M-5 (Underline is a CDR sequence)
  • Anti-Mac-1 antibody CDR sequence clone 28E07, 28E07-HH, 28E07-B1H, 28E07-B2H, 28E07-B3H, 28E07-B4H, 28E07-HB1, 28E07-HB2, 28E07-HB3, 28E07-HB4, 28E07-B1B1, 28E07-B1B2, 28E07-B2B1, and 28E07-B2B2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Monoclonal antibodies against human Mac-1 are provided. These antibodies can bind to different states of Mac-1 so as to alter the biofunctions of Mac-1. These antibodies can modulate Th1/Th2 cytokine secretions by TLR-activated immune cells and can be used for the treatments of diseases related to acute and chronic inflammatory disorders, such as infectious diseases, and cancers.

Description

MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND USES THEREOF
BACKGROUND OF INVENTION
[0001] Macrophage-1 antigen (Mac-1, integrin aM02) is mainly expressed on the surface of innate immune cells (including monocytes, neutrophils, NK cells, etc.). Mac-1 is a heterodimeric glycoprotein comprising non-covalently linked integrin aM (CD 11b, CR3A, ITGAM) and integrin 02 (CD18, ITGB2). CD1 lb is a transmembrane protein with alarge extracellular domain and a short cytoplasmic tail. Its extracellular domain comprises an I domain, a 0-propeller domain, a thigh domain, a calf-1 domain, and a calf-2 domain. The I domain of CDllb has around 179 amino acids inserting into the 0-propeller domain. This I domain is responsible for binding to promiscuous ligands (e.g., iC3b, fibrinogen, ICAM-1, CD40L, etc.) and participates in cell adhesion, migration, chemotaxis, and phagocytosis, and regulates inflammatory responses of innate immune cells.
[0002] Like other integrins, Mac-1 exists in distinct conformations with different ligand binding affinities. As shown in FIG 1, CD1 lb and CD18 are bent in a V shape with the I-domain close to the membrane to form an inactive Mac-1 (low affinity). Inside-out signaling changes the Mac-1 to an open conformation, extending the I domain away from the membrane for optimal ligand binding. One epitope located on the I-EGF2 of CD 18 is hidden in the bent conformation (inactive or closed state); this epitope becomes exposed and can be recognized by a monoclonal antibody (KIM127) in the extended or open state (J. Immunol. 2001; 166: 5629-5637). This conformational change also results in the rearrangement of the I domain site such that it becomes a high affinity site for ligand binding and forms an epitope for mAb m24 binding (Proc. Natl. Acad. Sci. USA. 2004; 101: 2333-2338). Such conformational changes accompanying ligand binding affinity changes are tied to Mac-1 functions.
SUMMARY OF THE INVENTION
[0003] Embodiments of the invention relate to antibodies that can bind specifically to Mac-1 and modulate immune cell functions. These antibodies may be used to treat various Mac-1 associated diseases or conditions, such as infectious diseases or cancers.
[0004] One aspect of the invention relates to antibodies against human Mac-1. An antibody against human Mac-1 in accordance with one embodiment of the invention comprises a lightchain variable region sequence and a heavy -chain variable region sequence selected from SEQ ID NO:1 through SEQ ID NO: 158 shown in Table I. [0005] One aspect of the invention relates to methods for treating a disorder associate with Mac-1. A method in accordance with one embodiment of the invention comprises administering to a subject in need thereof an effective amount of an antibody of the invention. The disorder is an acute or chronic inflammation. The disorder may be an infection or a cancer.
[0006] Other aspects of the invention would become apparent from the following description and the associated drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] FIG. 1 shows the two conformations of Mac-1 and their epitopes for activationsensitive mAbs.
[0008] FIG. 2 shows results of characterization of HEK293/Mac-1 using various antibodies. HEK293 cells were incubated in PBS (Mock) or PBS/MnCh (Mn2+). Bindings of isotype control IgG, a CD1 lb specific mAb (clone ICRF44), a CD18 specific mAb (clone 6.7), or P2 activationdependent mAbs (KIM127 and m24) were detected using flow cytometry.
[0009] FIG. 3A shows that representative anti-Mac-1 antibodies of the invention (DF3M-5, H4L2, m2396, 24G05, and 28E07-HH) predominantly bind to myeloid immune cells (monocytes and neutrophils). Other antibodies of the invention show similar properties.
[0010] FIG. 3B shows that clones m2396, DF3M-5, and 24G05 bind to mouse Mac-1 expressing cell line Raw264.7.
[0011] FIG. 4 shows examples of anti-Mac-1 antibodies that can modulate conformational changes of Mac-1 under PBS (Mock) or PBS/MnCh (Mn2+) conditions.
[0012] FIG. 5 shows that anti -Mac- 1 antibody treatments can modulate TLR4 agonist- induced Thl/Th2 cytokines responses in mice in vivo. Data are shown as the means ± SEM (4 mice per group).
[0013] FIG. 6 shows that anti-Mac-1 antibodies reduce tumor growths in A549 human lung tumor bearing humanized NOG-EXL mouse model in vivo. Data are shown as the means ± SEM (10 mice per group).
[0014] FIG. 7A shows that anti-Mac-1 antibody enhanced the expression of functional markers in myeloid cells isolated from HIV patients.
[0015] FIG. 7B shows that anti -Mac- 1 antibody reduced the virus load in PBMCs from HIV patients. DETAILED DESCRIPTION
[0016] Embodiments of the invention relate to antibodies that can bind specifically to Mac-1 and modulate immune cell functions. These antibodies may be used to treat various Mac-1 associated diseases or conditions, such as infectious diseases or cancers.
[0017] Human antibody and mouse antibody phage display libraries were constructed and screened to isolate clones carrying specific antibody genes that can recognize Mac-1. These anti- Mac-1 antibodies are shown to bind Mac-1 on the HEK293/Mac-1 cells and innate immune cells. These antibodies can selectively bind to different states of Mac-1 (bent or extended/open conformation) and modulate the conformational changes of Mac-1. These anti-Mac-1 antibodies are shown to modulate TLR-induced cytokine productions and therefore can be used to treat acute and chronic inflammatory disorders, such as infectious diseases (ref: WO 2020/033929 Al) and cancers (ref: WO 2019/177669 Al and WO 2016/197974 Al).
[0018] The following describes specific examples of various aspects of the invention. One skilled in the art would appreciate that these specific examples are for illustration only and that other modifications and variations are possible without departing from the scope of the invention.
Material and method
Reagents and antibodies
[0019] The antibodies and reagents used for flow cytometry are KIM 127 (hybridoma from ATCC), m24-PE (BioLegend), anti-CDl lb-APC (clone ICRF44, BioLegend), anti-CD18-APC (clone 6.7, BD), BSA (BioShop), Rat IgGlK-APC (BioLegend), and Rat IgGlK-PE (BioLegend). The KIM127 antibody and BSA were conjugated with CF647, i.e., labeled with CF647 labeling kit (CF Dye & Biotin SE Protein Labeling Kits, Biotium).
Cell culture and stable transfection
[0020] Stable transfection of human integrin Mac-1 in HEK293 cells (BCRC) was performed using jetP RIME® (PolyPlus) transfection protocols. Briefly, HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Coming), supplemented with 10% heat- inactivated fetal bovine serum (Gibco) and 50 lU/mL penicillin and streptomycin (Coming) at 37 °C. The cells were seeded at 8 x 105 cells/well on a 6-well plate (Coster). Next day, a mixture of the jetPRIME® reagent and 2 pg pcDN A3.1 /human CD18 expression plasmid carrying a hygromycin-resistance gene was added to the cells, and the cells were cultured for 24 hr. The selection antibiotic, hygromycin B (InvivoGen), was added at a concentration of 200 pg/ml, and half of the culture media containing the antibiotic were changed every 2 to 3 days. After 3 weeks, the CD18-expression cells were collected using the Cell Sorter (SH800Z, SONY) to pick up CD18-high expression cells and seeded at single cell/well and 5000 cells/well on a24-well plate (Coster) and a 6-well plate. Cells were maintained in DMEM medium with 10% heat-inactivated fetal bovine serum, 50 lU/mL penicillin and streptomycin, and 200 pg/ml Hygromycin B at 37 °C. After the cells were enriched, human CD18 expression was analyzed with anti-human CD18- APC (clone 6.7, BD) antibody by flow cytometry. The permanent HEK293/human CD18 cells (clone 2B4) were seeded at 6 x 105 cells/well on a 6-well plate. The transfection protocol for human CDllb was the same as above. Briefly, 2 pg pcDN A3.1 /human CDl lb plasmid was mixed with jetPRIME® reagent and added to cells. Next days, the selection antibiotics, 1 mg/ml G418 (InvivoGen) and 200 pg/ml Hygromycin B, were added, and the medium containing selection antibiotics was changed every 2 to 3 days. The Mac-1 expression was measured with anti-human CDllb-APC (clone ICRF44, BioLegend) and anti-hCD18-APC by flow cytometry. The stable clone 1-4 was picked up.
Flow cytometry
[0021] The HEK293/Mac-1 cells (clonel-4) were counted and washed twice with staining buffer (PBS containing 1% FBS, and 0.1% sodium azide). Cells were adjusted at a concentration of 1x105 cells/ml in staining buffer and treated with/without 0.25 mM MnCh (Sigma). Cells were treated with anti -Mac- 1 antibodies and fluorescent conjugated anti -human IgG4 antibodies and incubated for 15 mins. After washing with the staining buffer, the cells were analyzed by flow cytometry. In some examples, these cells were treated with the antibodies (ICRF44, KIM127, m24, or isotype control) in the presence or absence lOpg/ml anti-Mac-1 antibodies. The cells were then incubated at 37 °C for 30 min. After washing with the staining buffer, the cells were analyzed by flow cytometry.
Cytokine measurement
[0022] Balb/c mice (n=4/group) were intraperitoneally injected with 5 mg/kg LPS and 10 mg/kg anti -Mac- 1 antibodies for 4 hours. Murine Thl and Th2 cytokines in the serum were detected by ProcartaPlex MS (Thermo Fisher Scientific) according to the manufacturer instructions.
Protocol of cancer treatment
[0023] Human umbilical cord blood derived CD34+ cells were transplanted into NOG-EXL mice via the tail vein. About 10 weeks after transplantation, peripheral blood were collected from the humanized NOG-EXL animals under anesthesia and used for FACS analysis. The types, proportions, fluorescence intensities, and absolute counts of immune cells (T cells, B cells, dendritic cells, and monocyte cells) were analyzed. When the average hCD45+% > 15%, hCD3+ of hCD45+% > 3%, and hCD14+ of hCD45+% > 5%, the humanized NOG-EXL animals were used for the anti -cancer study.
[0024] Human lung cancer A549 cells were cultured in a 37 °C incubator containing 5% CO2 with 10% FBS in F-12K medium. The cells were sub-cultured within 10 passages before being inoculated into mice. A549 cells (5xl06 cells) were mixed with Matrigel (v/v 1:1) in a volume of 200 pl immediately before injection subcutaneously. Before inoculation, mice were anesthetized with 2-5% isoflurane.
[0025] When tumor volumes reached 20 - 50 mm3, tumor-bearing animals were grouped into 3 groups based on the frequency of macrophage in human CD45+ cells, the frequency of CD3+ cell in human CD45+ cells, and tumor volumes, each group contains 10 mice. The day of grouping was denoted as day 0. Mice were treated on day 0.
[0026] Tumor volume: The tumor volume was calculated as follows: V = (length x width2) / 2. Tumor volume was measured and recorded twice a week during inoculation, grouping, and during the dose period. Tumor growth inhibition (TGI) was calculated as follows: TGI= (1- (T/C))xl00%; T and C as the mean tumor volumes of the treatment and control groups, respectively, on the measurement day.
Protocol of infectious disease treatment
PBMC isolation from HIV patients
[0027] Fifteen HIV-1 infected patients receiving regular highly active antiretroviral therapy (ART) treatments with undetectable plasma viral load (<50 HIV-1 RNA copies/ml) and countable CD4 cells (count > 200/mm3) were recruited at National Taiwan University Hospital (Taipei, Taiwan). The clinical and laboratory data were collected and acquired from medical records. Each blood sample was processed within 24 hours after collection, and leukocytes were isolated for further examination. This study was approved by the Institutional Review Board of National Taiwan University Hospital (Taipei, Taiwan), and written informed consents were obtained from each participant.
[0028] Peripheral blood mononuclear cells (PBMC) were isolated from whole blood samples by means of Ficoll-Paque (Amersham Biosciences, Sweden) gradient centrifugation. Cells were cultured in 96-well U-bottom culture plates (2x105 cells/well) and resuspended in RPMI-1640 medium with 10% fetal bovine serum (FBS), 100 nM elvitegravir (Cayman), and 100 nM efavirenz (Cayman) in the presence of human IgG4 antibody (BioLegend) or anti -Mac- 1 antibody (clone H4L2) 10 pg/ml for 3 days.
Functional marker detection of PBMCs of HIV patients
[0029] Cell suspensions were incubated with Fc blocker (BD Bioscience) in PBS containing 1% FBS and 0.1% sodium azide before staining with fluorochrome-labeled antibodies. Antibodies against CDllb (clone ICRF44, BioLegend), CD86 (clone 2331, BioLegend), HLA- DR (clone L243, BioLegend), and CD80 (clone L307, BD) were used for marker staining. FVS786 viability staining was used to exclude dead cells from analysis. The mean fluorescence intensity of stained cells was measured by CytoFlex flow cytometry and analyzed by Kaluza software (Beckman Coulter).
Intracellular HIV virus detection- 2 long-terminal repeat (LTR)- DNA circles quantitation [0030] DNA of 3 day-cultured PBMC (3xl06 cells/well in a 24-well culture plate) treated with/without PMA (lOOng/ml) and ionomycin (1 pg/ml) in the presence of human IgG4 antibody (BioLegend) or Anti-Mac-1 antibody (H4L2, 10 pg/ml) was extracted with QIAamp DNA Blood Mini Kit (Qiagen, MD, USA) and DNA were eluted by 50pl nuclease-free water. Digital PCR was performed with the QX100™ Droplet Digital™ PCR platform (Bio-Rad, Hercules, California). The ddPCR mix was made by adding 1-5 pl of sample to 10 pl 2x ddPCR™ supermix for probes (Bio-Rad), Ipl EcoR, 500 nM of primers, and 250 nM of probe in a final volume of 20 pl. The mix was placed in an 8-channel cartridge, 70 pl of droplet generating oil (Bio-Rad) was added and droplets were generated in the QX100™ droplet generator (Bio-Rad). Droplet in oil suspensions were transferred to an ddPCR 96-well plate (Bio-Rad) and PCR was performed in the T100™ Thermal Cycler (Bio-Rad). DdPCR amplification reactions consisted of an initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec denaturation and 60°C for 60 sec annealing/elongation temperature, and enzyme deactivation at 98°C for 10 min. The ramping rate of each step is 2°C/sec. The sequences of primer pairs are listed in Table VI.
Statistical analysis
[0031] Results were compared by Fisher’s exact test for categorical variables and paired t test or unpaired t test for continuous variables as appropriate. Data are reported as the mean ± SEM. Statistical analysis was performed using Prism 9.0 software. Two-sided tests were used, and a p-value of < 0.05 was considered statistically significant.
Results
Expression of heterodimeric CDllb/CD18 (Mac-1) on HEK293 cell surface [0032] HEK293 cells, which do not express endogenous Mac-1, were transfected with pcDN A3.1 /human CDl lb and pcDN A3.1 /human CD18 plasmids using liposome transfections. After G418 and hygromycin selections, we obtained several single-cell clones stably expressing the human Mac-1 on the cell surface by FACS sorting using CD18-specific mAb (clone 6.7) and CDllb specific mAb (clone ICRF44). One clone, designated 1-4, was selected for all the examples presented in this description. Other clones show similar properties.
[0033] The expressions of CDllb and CD 18 on the HEK293 cells, as detected by flow cytometry, are shown in FIG 2. We verified the conformational state on the surface of HEK293/Mac-1 cells using two activation-sensitive antibodies, mAbs, KIM127 and m24. KIM127 can fully bind to HEK293/Mac-1, suggesting that Mac-1 is in the extended conformation. Little binding of m24 to HEK293/Mac-1 cells were observed in PBS (Mock), suggesting that Mac-1 is in the low affinity state. The HEK293/Mac-1 in the PBS is partially activated. In contrast, Mn2+ treatment induced 100% of Mac- 1 molecule to adopt an extended, high-affinity conformation. Thus, these cells provide an excellent platform for the screening of monoclonal antibodies of human Mac-1.
Anti-Mac- 1 antibodies selectively bind to the different states of Mac- 1 on HEK293/Mac-l cell surface
[0034] We constructed human antibody and mouse antibody phage display libraries and then screened and isolated clones carrying specific antibody genes that can recognize Mac-1. A total of 79 clones were picked from the phage pools from each round of selection. The amino acid sequences of the variable regions of these clones are listed in Table I and Table VII. To verify that these clones can bind to Mac-1 in its native conformation, we generated recombinant antibodies from these clones with human IgG4 backbone. The recombinant anti -Mac- 1 antibodies were used in flow cytometric analysis of HEK293/Mac-1 cells. As listed in Table II, these antibodies can indeed recognize Mac-1 on the surface of HEK293/Mac-1 cells.
[0035] Conformational change of Mac-1 is involved in the regulation of its functions. We examine whether these antibodies can recognize different conformations of Mac-1. As listed in Table II, some clones selectively bind to an activation-specific epitope on Mac-1 molecules on HEK293/Mac-1 cells after stimulation with Mn2+ (Mock/MnCh Ratio < 1). In contrast, some clones preferentially recognize the resting form of Mac-1 (Mock/MnCh Ratio > 1). The deduced amino-acid sequences of the CDRs and framework regions of selected clones are shown in Table I. Anti-Mac- 1 antibodies predominantly bind to Mac-1 on the innate immune cell surface [0036] The innate immune cells such as monocytes (CD14+ cells) and neutrophils (CD66b+ cells) are the main cells that express Mac-1 on their cell surface. Some populations of B cells also expressed Mac-1 on their cell surface (Proc Natl Acad Sci U S A. 2008 Apr 1; 105(13):5195- 200). The specificities of selective anti-Mac-1 antibodies were determined by flow cytometry using human whole blood. As shown in FIG. 3A, anti-Mac-1 antibodies in this example were able to bind to the innate immune cells (CD14+ and CD66b+ cells) and small populations of B cells (CD19+ cells). In contrast, these antibodies did not bind to T cells (CD3+ lymphocytes). Taken together, these results indicate that anti-Mac-1 antibodies can specifically bind to the Mac-1 epitope on the immune cells. To determine whether an anti-Mac-1 antibody validated for human Mac-1 will cross-react with the mouse Mac-1, we use Raw 264.7 mouse macrophage cell line that expressed mouse Mac-1 on the cell surface. As shown in FIG. 3B, some clones, such as DF3M-5, m2396, and 24G05, can bind to the surface of Raw 264.7, suggesting that these clones can cross react with mouse Mac-1.
Anti -Mac- 1 antibodies induce a conformational change in Mac-1
[0037] It is well known that inside-out signaling induces global conformational changes of Mac-1 leading to outside-in signaling. To screen which anti -Mac- 1 antibodies would induce conformational changes in Mac-1, we used KIM127 and m24 antibodies, which bind preferentially to Mac-1 in the extended conformation, as reporters to detect conformational changes. As shown in FIG. 4 left panel, incubation of the antibodies with HEK293/Mac-1 cells in PBS buffer (Mock) resulted in basal levels of KIMI 27 and m24 bindings. In contrast, incubation of the antibodies with HEK293/Mac-1 cells in MnCh/PBS buffer (Mn2+) induced maximal levels of KIM127 and m24 bindings (FIG.4 right panel). Incubation with DF3M-5 in the Mock condition induced a small increase in KIM127 binding and a large increase in m24 binding (FIG. 4 left panel), indicating that this DF3M-5 clone can serve as an agonist to enhance the conformational change of Mac-1. Other clones that can serve as agonists (based on m24 expression relative IgG4 control >1) are listed in Table III. In contrast, incubation with 28E07 in the Mn2+ condition induces a small decrease in KIM 127 binding and a large decrease in m24 binding (FIG. 4 right), indicating that this 28E07 clone can serve as an antagonist to reduce the conformational change of Mac-1. Other clones that can serve as antagonists (based on m24 expression relative IgG4 control <1) are listed in Table IV. Results from these studies indicate that antibodies of the invention may be selectively used to control the conformational changes of Mac- 1, thereby regulating the functions of Mac- 1. Anti-Mac-1 antibodies modulate Thl/Th2 cytokine secretion by TLR-activated immune cells in vivo,
[0038] Previous studies show that active CD 11b integrin engages in crosstalks with the MyD88 and TRIF pathways and modulate TLR signaling in innate immune responses (Nat Immunol. 2010 Aug; 11 (8): 734-42). To examine whether anti-Mac-1 antibodies of the invention can modulate Thl/Th2 cytokine secretions in TLR-activated immune cells in vivo, Balb/c mice (n=4/group) were intraperitoneal injected with 5 mg/kg LPS and 10 mg/kg anti-Mac-1 antibodies. Four hours later, serum Thl/Th2 cytokines were measured by ProcartaPlex™ MS. As shown in FIG 5, m2396 and DF3M-5 treatments enhanced TLR4-induced Thl cytokines (such as IFN-y, IL-1 , and TNF-a) and slightly enhance TLR4-induced Th2 cytokines (such as IL-5 and IL-13) in the serum. These results suggest that anti-Mac-1 antibody (clones m2396 and DF3M-5) treatment can skew the TLR-induced Thl/Th2 responses. In contrast, 24G05 treatment didn’t alter Thl/Th2 cytokine profile.
Anti-Mac- 1 antibody treatment reduces tumor growth
[0039] The anti-cancer activities of the anti-Mac-1 antibodies of the invention (e.g., m2396 and 28E07-HH) were further evaluated in the treatment of A549 cancer model in female NOG- EXL humanized mice.
[0040] When the average tumor volumes reached about 41 mm3, tumor bearing mice were randomized into 3 groups (Human IgG4, m2396, and 28E07-HH) and the treatments were started. The mean tumor sizes of mice reached 172.59 mm3 in Human IgG4 group, 132.51 mm3 in m2396 group, and 109.88 mm3 in 28E07-HH group on Day35 post grouping (FIG. 6). FIG. 6 shows results from representative antibodies m2396 and 28E07-HH. Other antibodies of the invention have similar properties. The tumor growth inhibition (TGI) % of the m2396 group and 28E07-HH group were 23.59%, and 35.93%, respectively. The TGI of the different groups at different time points were shown in Table V. These results indicate that these anti -Mac- 1 antibodies can serve as therapeutic antibodies to treat human cancer.
Anti-Mac- 1 antibody treatment reduced HIV viral load and reverses immunosuppressed phenotype of PBMC in HIV patients
[0041] To test the efficacy of the anti-Mac-1 antibody-mediated inhibitory actions against HIV, PBMC isolated from fifteen latent HIV -infected patients were treated with anti -Mac- 1 antibodies for 3 days in vitro. As shown in FIG 7A, the anti-Mac-1 antibody (H4L2 shown as a representative of anti-Mac-1 antibodies) significantly enhanced the expression of CD86 and MHC class II functional markers in myeloid cells of HIV patients. These results indicate that enhanced T cell activation and dendritic cells (DCs) maturation in HIV patients can be achieved with the anti-Mac-1 antibodies of the present invention. These enhanced immune responses may suggest a potential application for the antibodies of the invention in the treatment of HIV infection.
[0042] While combination antiretroviral therapy (ART) may suppress HIV replication. HIV- 1 persists in the infected cells as a stable integrated genome and more labile unintegrated DNA, which includes linear, 1-LTR and 2-LTR circular DNA. 2-LTR circle DNA, although less abundant, is considered a surrogate marker for recent infection events and is currently used as a diagnostic tool. (C. Orlandi et al., “A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication,” J. Transl. Med. 18, 204 (2020). Doi: 10.1186/sl2967- 020-02368-y).
[0043] To detect the load of intracellular HIV virus, HIV virus DNA reservoir was quantified using the 2 long-terminal repeat (LTR) DNA circles as the marker. Because these fifteen HIV-1 infected patients were receiving regular highly active antiretroviral therapy (ART) treatments, only 3 of the 15 patients had detectable levels of the HIV DNA by the LTR assay. Nevertheless, declines in the HIV 2LTR DNA levels were observed in these 3 patients’ PBMC samples treated with the anti -Mac- 1 antibody or with the anti-Mac-1 antibody in combination with phorbol 12- myristate 13-acetate (PMA) and ionomycin (FIG. 7B).
[0044] While the invention has been described with a limited number of examples, one skilled in the art would appreciate that these examples are for illustration only and that other modifications and variations are possible without departing from the scope of the invention. Therefore, the scope of protection should only be limited by the attached claims.
Tables
Table I: Heavy-chain variable region sequences and light-chain variable region sequences of SEQ ID NO:1 through SEQ ID NO:158
Anti-Mac- 1 antibody sequence clone: 24F08 (Underline is a CDR sequence)
Figure imgf000013_0001
Anti-Mac- 1 antibody sequence clone: 24F09 (Underline is a CDR sequence)
Figure imgf000013_0002
Anti-Mac- 1 antibody sequence clone: 24F11 (Underline is a CDR sequence)
Figure imgf000013_0003
Anti-Mac- 1 antibody sequence clone: 24F12 (Underline is a CDR sequence)
Figure imgf000014_0001
Anti-Mac-1 antibody sequence clone: 24G01 (Underline is a CDR sequence)
Figure imgf000014_0002
Anti-Mac- 1 antibody sequence clone: 24G05 (Underline is a CDR sequence)
Figure imgf000014_0003
Anti-Mac- 1 antibody sequence clone: 24G07 (Underline is a CDR sequence)
Figure imgf000014_0004
Figure imgf000015_0001
Anti-Mac- 1 antibody sequence clone: 24G08 (Underline is a CDR sequence)
Figure imgf000015_0002
Anti-Mac- 1 antibody sequence clone: 24G09 (Underline is a CDR sequence)
Figure imgf000015_0003
Anti-Mac- 1 antibody sequence clone: 24G10 (Underline is a CDR sequence)
Figure imgf000015_0004
Figure imgf000016_0001
Anti-Mac- 1 antibody sequence clone: 24G11 (Underline is a CDR sequence)
Figure imgf000016_0002
Anti-Mac-1 antibody sequence clone: 24G12 (Underline is a CDR sequence)
Figure imgf000016_0003
Anti-Mac-1 antibody sequence clone: 24H01 (Underline is a CDR sequence)
Figure imgf000016_0004
Figure imgf000017_0001
Anti-Mac- 1 antibody sequence clone: 24H02 (Underline is a CDR sequence)
Figure imgf000017_0002
Anti-Mac- 1 antibody sequence clone: 24H03 (Underline is a CDR sequence)
Figure imgf000017_0003
Anti-Mac- 1 antibody sequence clone: 25A02 (Underline is a CDR sequence)
Figure imgf000017_0004
Anti-Mac- 1 antibody sequence clone: 25A04 (Underline is a CDR sequence)
Figure imgf000018_0001
Anti-Mac- 1 antibody sequence clone: 25A06 (Underline is a CDR sequence)
Figure imgf000018_0002
Anti-Mac- 1 antibody sequence clone: 25A09 (Underline is a CDR sequence)
Figure imgf000018_0003
Anti-Mac- 1 antibody sequence clone: 25A10 (Underline is a CDR sequence)
Figure imgf000018_0004
Figure imgf000019_0001
Anti-Mac- 1 antibody sequence clone: 25B03 (Underline is a CDR sequence)
Figure imgf000019_0002
Anti-Mac- 1 antibody sequence clone: 25B04 (Underline is a CDR sequence)
Figure imgf000019_0003
Anti-Mac- 1 antibody sequence clone: 25B01 (Underline is a CDR sequence)
Figure imgf000019_0004
Figure imgf000020_0001
Anti-Mac-1 antibody sequence clone: DF3-10 (Underline is a CDR sequence)
Figure imgf000020_0002
Anti-Mac-1 antibody sequence clone: DF3-28 (Underline is a CDR sequence)
Figure imgf000020_0003
Anti-Mac-1 antibody sequence clone: DF3-30 (Underline is a CDR sequence)
Figure imgf000020_0004
Figure imgf000021_0001
Anti-Mac-1 antibody sequence clone: DF3-32 (Underline is a CDR sequence)
Figure imgf000021_0002
Anti-Mac- 1 antibody sequence clone: DF4-16 (Underline is a CDR sequence)
Figure imgf000021_0003
Anti-Mac- 1 antibody sequence clone: DF4-17 (Underline is a CDR sequence)
Figure imgf000021_0004
Figure imgf000022_0001
Anti-Mac- 1 antibody sequence clone: DF4-22 (Underline is a CDR sequence)
Figure imgf000022_0002
Anti-Mac- 1 antibody sequence clone: DF4-25 (Underline is a CDR sequence)
Figure imgf000022_0003
Anti-Mac- 1 antibody sequence clone: DF4-26 (Underline is a CDR sequence)
Figure imgf000022_0004
Anti-Mac- 1 antibody sequence clone: DF4-42 (Underline is a CDR sequence)
Figure imgf000023_0001
Anti-Mac- 1 antibody sequence clone: DF3M-1 (Underline is a CDR sequence)
Figure imgf000023_0002
Anti-Mac- 1 antibody sequence clone: DF3M-2 (Underline is a CDR sequence)
Figure imgf000023_0003
Anti-Mac- 1 antibody sequence clone: DF3M-5 (Underline is a CDR sequence)
Figure imgf000023_0004
Figure imgf000024_0001
Anti-Mac-1 antibody sequence clone: DF3M-18 (Underline is a CDR sequence)
Figure imgf000024_0002
Anti-Mac- 1 antibody sequence clone: DF3M-19 (Underline is a CDR sequence)
Figure imgf000024_0003
Anti-Mac-1 antibody sequence clone: DF3M-30 (Underline is a CDR sequence)
Figure imgf000024_0004
Figure imgf000025_0001
Anti-Mac-1 antibody sequence clone: DF3M-36 (Underline is a CDR sequence)
Figure imgf000025_0002
Anti-Mac- 1 antibody sequence clone: DF3M-42 (Underline is a CDR sequence)
Figure imgf000025_0003
Anti-Mac- 1 antibody sequence clone: DF4M-1 (Underline is a CDR sequence)
Figure imgf000025_0004
Figure imgf000026_0001
Anti-Mac- 1 antibody sequence clone: DF4M-3 (Underline is a CDR sequence)
Figure imgf000026_0002
Anti-Mac-1 antibody sequence clone: DF4M-7-1 (Underline is a CDR sequence)
Figure imgf000026_0003
Anti-Mac- 1 antibody sequence clone: DF4M-7-4 (Underline is a CDR sequence)
Figure imgf000026_0004
Anti-Mac- 1 antibody sequence clone: DF4M-9 (Underline is a CDR sequence)
Figure imgf000027_0001
Anti-Mac-1 antibody sequence clone: DF4M-11 (Underline is a CDR sequence)
Figure imgf000027_0002
Anti-Mac- 1 antibody sequence clone: DF4M-17 (Underline is a CDR sequence)
Figure imgf000027_0003
Anti-Mac-1 antibody sequence clone: DF4M-18 (Underline is a CDR sequence)
Figure imgf000027_0004
Figure imgf000028_0001
Anti-Mac- 1 antibody sequence clone: DF4M-21 (Underline is a CDR sequence)
Figure imgf000028_0002
Anti-Mac- 1 antibody sequence clone: DF4M-23 (Underline is a CDR sequence)
Figure imgf000028_0003
Anti-Mac-1 antibody sequence clone: DF4M-30 (Underline is a CDR sequence)
Figure imgf000028_0004
Figure imgf000029_0001
Anti-Mac-1 antibody sequence clone: DF4M-31 (Underline is a CDR sequence)
Figure imgf000029_0002
Anti-Mac- 1 antibody sequence clone: DF4M-45 (Underline is a CDR sequence)
Figure imgf000029_0003
Anti-Mac- 1 antibody sequence clone: 28E07 (Underline is a CDR sequence)
Figure imgf000029_0004
Figure imgf000030_0001
Anti-Mac-1 antibody sequence clone: 28A12 (Underline is a CDR sequence)
Figure imgf000030_0002
Anti-Mac-1 antibody sequence clone: 27G04 (Underline is a CDR sequence)
Figure imgf000030_0003
Anti-Mac- 1 antibody sequence clone: 27A04 (Underline is a CDR sequence)
Figure imgf000030_0004
Figure imgf000031_0001
Anti-Mac- 1 antibody sequence clone: 27A06 (Underline is a CDR sequence)
Figure imgf000031_0002
Anti-Mac- 1 antibody sequence clone: 28G06 (Underline is a CDR sequence)
Figure imgf000031_0003
Anti-Mac- 1 antibody sequence clone: 27B10 (Underline is a CDR sequence)
Figure imgf000031_0004
Anti-Mac- 1 antibody sequence clone: 27D06 (Underline is a CDR sequence)
Figure imgf000032_0001
Anti-Mac- 1 antibody sequence clone: 28D06 (Underline is a CDR sequence)
Figure imgf000032_0002
Anti-Mac-1 antibody sequence clone: 27E12 (Underline is a CDR sequence)
Figure imgf000032_0003
Anti-Mac-1 antibody sequence clone: m2396 (Underline is a CDR sequence)
Figure imgf000032_0004
Figure imgf000033_0001
Anti-Mac- 1 antibody sequence clone: H4L2 (Underline is a CDR sequence)
Figure imgf000033_0002
Anti-Mac- 1 antibody sequence clone: 28E07-HH (Underline is a CDR sequence)
Figure imgf000033_0003
Anti-Mac-1 antibody sequence clone: 28E07-B1H (Underline is a CDR sequence)
Figure imgf000033_0004
Figure imgf000034_0001
Anti-Mac- 1 antibody sequence clone: 28E07-B2H (Underline is a CDR sequence)
Figure imgf000034_0002
Anti-Mac- 1 antibody sequence clone: 28E07-B3H (Underline is a CDR sequence)
Figure imgf000034_0003
Anti-Mac- 1 antibody sequence clone: 28E07-B4H (Underline is a CDR sequence)
Figure imgf000034_0004
Figure imgf000035_0001
Anti-Mac- 1 antibody sequence clone: 28E07-HB1 (Underline is a CDR sequence)
Figure imgf000035_0002
Anti-Mac- 1 antibody sequence clone: 28E07-HB2 (Underline is a CDR sequence)
Figure imgf000035_0003
Anti-Mac- 1 antibody sequence clone: 28E07-HB3 (Underline is a CDR sequence)
Figure imgf000035_0004
Anti-Mac- 1 antibody sequence clone: 28E07-HB4 (Underline is a CDR sequence)
Figure imgf000036_0001
Anti-Mac- 1 antibody sequence clone: 28E07-B1B1 (Underline is a CDR sequence)
Figure imgf000036_0002
Anti-Mac- 1 antibody sequence clone: 28E07-B1B2 (Underline is a CDR sequence)
Figure imgf000036_0003
Anti-Mac- 1 antibody sequence clone: 28E07-B2B1 (Underline is a CDR sequence)
Figure imgf000036_0004
Figure imgf000037_0001
Anti-Mac- 1 antibody sequence clone: 28E07-B2B2 (Underline is a CDR sequence)
Figure imgf000037_0002
Table II: The anti-Mac-1 antibodies selectively bind to different statuses of human Mac-1.
HEK293/Mac-1 cells (clonel-4) were incubated in PBS (Mock), or PBS/MnCh (Mn2+).
Binding of isotype control IgG, the CDllb specific mAb (ICRF44), the CDllb activationsensing mAh (CBRM1/5), or the screened anti-Mac-1 antibody was detected using flow cytometry.
Figure imgf000037_0003
Figure imgf000038_0001
Table III: The anti-Mac-1 antibodies can serve as agonist to enhance the conformational change of Mac- 1. HEK293/Mac-1 cells (clonel-4) were incubated with 10 pg/ml anti-Mac-1 antibodies under the PBS (Mock) condition. Binding of KIM127 or m24 was detected using flow cytometry.
Figure imgf000038_0002
Figure imgf000039_0001
Table IV: The anti-Mac-1 antibody can serve as an antagonist to reduce the conformational change of Mac- 1. HEK293/Mac-1 cells (clonel-4) were incubated with 10 Hg/ml anti-Mac-1 antibodies under the PBS/MnCh (Mn2+) condition. Binding of KIMI 27 or m24 was detected using flow cytometry.
Figure imgf000039_0002
Figure imgf000040_0001
Table V: Tumor growth inhibition (TGI, %)
Figure imgf000040_0002
Figure imgf000041_0001
Table VI: Primer and probe sequences used in digital PCR
Figure imgf000041_0002
Table VII: Heavy-chain CDR region sequences and light-chain CDR region sequences of
SEQ ID NO: 159 through SEQ ID NO: 554
Anti-Mac- 1 antibody CDR sequence clone: 24F08
Figure imgf000041_0003
Figure imgf000042_0001
Anti-Mac- 1 antibody CDR sequence clone: 24F09
Figure imgf000042_0002
Anti-Mac- 1 antibody CDR sequence clone: 24F11
Figure imgf000042_0003
Anti-Mac- 1 antibody CDR sequence clone: 24F12
Figure imgf000042_0004
Anti-Mac-1 antibody CDR sequence clone: 24G01
Figure imgf000042_0005
Figure imgf000043_0001
Anti-Mac- 1 antibody CDR sequence clone: 24G05
Figure imgf000043_0002
Anti-Mac- 1 antibody CDR sequence clone: 24G07
Figure imgf000043_0003
Anti-Mac- 1 antibody CDR sequence clone: 24G08
Figure imgf000043_0004
Anti-Mac- 1 antibody CDR sequence clone: 24G09
Figure imgf000044_0001
Anti-Mac- 1 antibody CDR sequence clone: 24G10
Figure imgf000044_0002
Anti-Mac-1 antibody CDR sequence clone: 24G11
Figure imgf000044_0003
Anti-Mac-1 antibody CDR sequence clone: 24G12
Figure imgf000044_0004
Figure imgf000045_0001
Anti-Mac-1 antibody CDR sequence clone: 24H01
Figure imgf000045_0002
Anti-Mac- 1 antibody CDR sequence clone: 24H02
Figure imgf000045_0003
Anti-Mac- 1 antibody sequence clone: 24H03 (Underline is a CDR sequence)
Figure imgf000045_0004
Anti-Mac- 1 antibody CDR sequence clone: 25A02
Figure imgf000045_0005
Figure imgf000046_0001
Anti-Mac- 1 antibody CDR sequence clone: 25A04
Figure imgf000046_0002
Anti-Mac- 1 antibody CDR sequence clone: 25A06
Figure imgf000046_0003
Anti-Mac- 1 antibody CDR sequence clone: 25A09
Figure imgf000046_0004
Anti-Mac- 1 antibody CDR sequence clone: 25A10
Figure imgf000047_0001
Anti-Mac- 1 antibody sequence clone: 25B03 (Underline is a CDR sequence)
Figure imgf000047_0002
Anti-Mac- 1 antibody CDR sequence clone: 25B04
Figure imgf000047_0003
Anti-Mac- 1 antibody CDR sequence clone: 25B01
Figure imgf000047_0004
Figure imgf000048_0001
Anti-Mac-1 antibody CDR sequence clone: DF3-10
Figure imgf000048_0002
Anti-Mac-1 antibody CDR sequence clone: DF3-28
Figure imgf000048_0003
Anti-Mac-1 antibody CDR sequence clone: DF3-30
Figure imgf000048_0004
Anti-Mac-1 antibody CDR sequence clone: DF3-32
Figure imgf000048_0005
Figure imgf000049_0001
Anti-Mac-1 antibody CDR sequence clone: DF4-16
Figure imgf000049_0002
Anti-Mac-1 antibody CDR sequence clone: DF4-17
Figure imgf000049_0003
Anti-Mac- 1 antibody CDR sequence clone: DF4-22
Figure imgf000049_0004
Anti-Mac- 1 antibody CDR sequence clone: DF4-25
Figure imgf000050_0001
Anti-Mac- 1 antibody CDR sequence clone: DF4-26
Figure imgf000050_0002
Anti-Mac- 1 antibody CDR sequence clone: DF4-42
Figure imgf000050_0003
Anti-Mac- 1 antibody CDR sequence clone: DF3M-1
Figure imgf000050_0004
Figure imgf000051_0001
Anti-Mac- 1 antibody CDR sequence clone: DF3M-2
Figure imgf000051_0002
Anti-Mac- 1 antibody sequence clone: DF3M-5 (Underline is a CDR sequence)
Figure imgf000051_0003
Anti-Mac-1 antibody CDR sequence clone: DF3M-18
Figure imgf000051_0004
Anti-Mac- 1 antibody CDR sequence clone: DF3M-19
Figure imgf000051_0005
Figure imgf000052_0001
Anti-Mac-1 antibody CDR sequence clone: DF3M-30
Figure imgf000052_0002
Anti-Mac-1 antibody CDR sequence clone: DF3M-36
Figure imgf000052_0003
Anti-Mac- 1 antibody CDR sequence clone: DF3M-42
Figure imgf000052_0004
Anti-Mac- 1 antibody CDR sequence clone: DF4M-1
Figure imgf000053_0001
Anti-Mac- 1 antibody CDR sequence clone: DF4M-3
Figure imgf000053_0002
Anti-Mac- 1 antibody CDR sequence clone: DF4M-7-1
Figure imgf000053_0003
Anti-Mac- 1 antibody CDR sequence clone: DF4M-7-4
Figure imgf000053_0004
Figure imgf000054_0001
Anti-Mac- 1 antibody CDR sequence clone: DF4M-9
Figure imgf000054_0002
Anti-Mac-1 antibody CDR sequence clone: DF4M-11
Figure imgf000054_0003
Anti-Mac- 1 antibody CDR sequence clone: DF4M-17
Figure imgf000054_0004
Anti-Mac-1 antibody CDR sequence clone: DF4M-18
Figure imgf000054_0005
Figure imgf000055_0001
Anti-Mac- 1 antibody CDR sequence clone: DF4M-21
Figure imgf000055_0002
Anti-Mac- 1 antibody CDR sequence clone: DF4M-23
Figure imgf000055_0003
Anti-Mac-1 antibody CDR sequence clone: DF4M-30
Figure imgf000055_0004
Anti-Mac-1 antibody CDR sequence clone: DF4M-31
Figure imgf000056_0001
Anti-Mac- 1 antibody CDR sequence clone: DF4M-45
Figure imgf000056_0002
Anti-Mac-1 antibody CDR sequence clone: 28E07, 28E07-HH, 28E07-B1H, 28E07-B2H, 28E07-B3H, 28E07-B4H, 28E07-HB1, 28E07-HB2, 28E07-HB3, 28E07-HB4, 28E07-B1B1, 28E07-B1B2, 28E07-B2B1, and 28E07-B2B2
Figure imgf000056_0003
Anti-Mac-1 antibody CDR sequence clone: 28A12
Figure imgf000056_0004
Figure imgf000057_0001
Anti-Mac-1 antibody CDR sequence clone: 27G04
Figure imgf000057_0002
Anti-Mac- 1 antibody CDR sequence clone: 27A04
Figure imgf000057_0003
Anti-Mac- 1 antibody CDR sequence clone: 27A06
Figure imgf000057_0004
Anti-Mac- 1 antibody CDR sequence clone: 28G06
Figure imgf000058_0001
Anti-Mac- 1 antibody CDR sequence clone: 27B10
Figure imgf000058_0002
Anti-Mac- 1 antibody CDR sequence clone: 27D06
Figure imgf000058_0003
Anti-Mac- 1 antibody CDR sequence clone: 28D06
Figure imgf000058_0004
Figure imgf000059_0001
Anti-Mac-1 antibody CDR sequence clone: 27E12
Figure imgf000059_0002
Anti-Mac-1 antibody CDR sequence clone: m2396
Figure imgf000059_0003
Anti-Mac- 1 antibody CDR sequence clone: H4L2
Figure imgf000059_0004

Claims

58 Claims What is claimed is:
1. An antibody against human Mac-1, wherein the antibody binds to a specific state of human Mac-1 and modulates Thl and/or Th2 cytokine secretions by TLR-activated immune cells.
2. The antoby according to claim 1, wherein the Thl cytokine secretion is enhanced to a greater extent than the Th2 ctokine secretion.
3. The antibody according to claim 1, wherein the antibody comprises a heavy-chain variable region sequence having CDR-H1, CDR-H2, and CDR-H3 sequences; and a light-chain variable region sequence having CDR-L1, CDR-L2, and CDR-L3 sequences, wherein the CDR-H1 has the sequence of SEQ ID NO: 543, 549, 483, 369, 189, 159, 165,
171, 177, 183, 195, 201, 207, 213, 219, 225, 231, 237, 243, 249, 255, 261,
267, 273, 279, 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351,
357, 363, 375, 381, 387, 393, 399, 405, 411, 417, 423, 429, 435, 441, 447,
453, 459, 465, 471, 477, 489, 495, 501, 507, 513, 519, 525, 531, or 537; the CDR-H2 has the sequence of SEQ ID NO: 544, 550, 484, 370, 190, 160, 166,
172, 178, 184, 196, 202, 208, 214, 220, 226, 232, 238, 244, 250, 256, 262,
268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352,
358, 364, 376, 382, 388, 394, 400, 406, 412, 418, 424, 430, 436, 442, 448,
454, 460, 466, 472, 478, 490, 496, 502, 508, 514, 520, 526, 532, or 538; the CDR-H3 has the sequence of SEQ ID NO: 545, 551, 485, 371, 191, 161, 167,
173, 179, 185, 197, 203, 209, 215, 221, 227, 233, 239, 245, 251, 257, 263,
269, 275, 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353,
359, 365, 377, 383, 389, 395, 401, 407, 413, 419, 425, 431, 437, 443, 449,
455, 461, 467, 473, 479, 491, 497, 503, 509, 515, 521, 527, 533, or 539; the CDR-L1 has the sequence of SEQ ID NO: 546, 552, 486, 372, 192, 162, 168,
174, 180, 186, 198, 204, 210, 216, 222, 228, 234, 240, 246, 252, 258, 264,
270, 276, 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354,
360, 366, 378, 384, 390, 396, 402, 408, 414, 420, 426, 432, 438, 444, 450,
456, 462, 468, 474, 480, 492, 498, 504, 510, 516, 522, 528, 534, or 540; the CDR-L2 has the sequence of SEQ ID NO: 547, 553, 487, 373, 193, 163, 169, 59
175, 181, 187, 199, 205, 211, 217, 223, 229, 235, 241, 247, 253, 259, 265,
271, 277, 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355,
361, 367, 379, 385, 391, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451,
457, 463, 469, 475, 481, 493, 499, 505, 511, 517, 523, 529, 535, or 541; and the CDR-L3 has the sequence of SEQ ID NO: 548, 554, 488, 374, 194, 164, 170,
176, 182, 188, 200, 206, 212, 218, 224, 230, 236, 242, 248, 254, 260, 266,
272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356,
362, 368, 380, 386, 392, 398, 404, 410, 416, 422, 428, 434, 440, 446, 452,
458, 464, 470, 476, 482, 494, 500, 506, 512, 518, 524, 530, 536, or 542. The antibody against human Mac-1 according to claim 1, wherein the CDR-H1, CDR- H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 have the sequences of SEQ ID NO: 159-164, or SEQ ID NO: 165-170, or SEQ ID NO: 171-176, or SEQ ID NO: 177-182, or SEQ ID NO: 183-188, or SEQ ID NO: 189-194, or SEQ ID NO: 195-200, or SEQ ID NO: 201-206, or SEQ ID NO: 207-212, or SEQ ID NO: 213-218, or SEQ ID NO: 219-224, or SEQ ID NO: 225-230, or SEQ ID NO: 231-236, or SEQ ID NO: 237-242, or SEQ ID NO: 243-248, or SEQ ID NO: 249-254, or SEQ ID NO: 255-260, or SEQ ID NO: 261-266, or SEQ ID NO: 267-272, or SEQ ID NO: 273-278, or SEQ ID NO: 279-284, or SEQ ID NO: 285-290, or SEQ ID NO: 291-296, or SEQ ID NO: 297-302, or SEQ ID NO: 303-308, or SEQ ID NO: 309-314, or SEQ ID NO: 315-320, or SEQ ID NO: 321-326, or SEQ ID NO: 327-332, or SEQ ID NO: 333-338, or SEQ ID NO: 339-344, or SEQ ID NO: 345-350, or SEQ ID NO: 351-356, or SEQ ID NO: 357-362, or SEQ ID NO: 363-368, or SEQ ID NO: 369-374, or SEQ ID NO: 375-380, or SEQ ID NO: 381-386, or SEQ ID NO: 387-392, or SEQ ID NO: 393-398, or SEQ ID NO: 399-404, or SEQ ID NO: 405-410, or SEQ ID NO: 411-416, or SEQ ID NO: 417-422, or SEQ ID NO: 423-428, or SEQ ID NO: 429-434, or SEQ ID NO: 435-440, or SEQ ID NO: 441-446, or SEQ ID NO: 447-452, or SEQ ID NO: 453-458, or SEQ ID NO: 459-464, or SEQ ID NO: 465-470, or SEQ ID NO: 471-476, or SEQ ID NO: 477-482, or SEQ ID NO: 483-488, or SEQ ID NO: 489-494, or SEQ ID NO: 495-500, or SEQ ID NO: 501-506, or SEQ ID NO: 507-512, or SEQ ID NO: 513-518, or SEQ ID NO: 519-524, or SEQ ID NO: 525-530, or SEQ ID NO: 531-536, or SEQ ID NO: 537-542, or SEQ ID NO: 543-548, or SEQ ID NO: 549-554. The antibody against human Mac-1 according to claim 1, wherein the CDR-H1, CDR- H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 have the sequences of SEQ ID NO: 60
543-548, or SEQ ID NO: 549-554, or SEQ ID NO: 483-488, or SEQ ID NO: 369-374, or SEQ ID NO: 189-194. The antibody against human Mac-1 according to claim 1, wherein the heavy-chain variable region sequence is SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, or 157; and the light-chain variable region sequence is SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, or 158. The antibody against human Mac-1 according to claim 1, wherein the heavy-chain variable region sequence and the light-chain variable region sequence have the following sequence pair: SEQ ID NO: 1 and 2, or SEQ ID NO:3 and 4, or SEQ ID NO:5 and 6, or SEQ ID NO:7 and 8, or SEQ ID NO:9 and 10, or SEQ ID NO: 11 and 12, or SEQ ID NO: 13 and 14, or SEQ ID NO: 15 and 16, or SEQ ID NO: 17 and 18, or SEQ ID NO: 19 and 20, or SEQ ID NO:21 and 22, or SEQ ID NO:23 and 24, or SEQ ID NO:25 and 26, or SEQ ID NO:27 and 28, or SEQ ID NO:29 and 30, or SEQ ID NO: 31 and 32, or SEQ ID NO:33 and 34, or SEQ ID NO:35 and 36, or SEQ ID NO:37 and 38, or SEQ ID NO: 39 and 40, or SEQ ID NO:41 and 42, or SEQ ID NO: 43 and 44, or SEQ ID NO:45 and 46, or SEQ ID NO:47 and 48, or SEQ ID NO:49 and 50, or SEQ ID NO:51 and 52, or SEQ ID NO:53 and 54, or SEQ ID NO:55 and 56, or SEQ ID NO:57 and 58, or SEQ ID NO:59 and 60, or SEQ ID NO:61 and 62, or SEQ ID NO:63 and 64, or SEQ ID NO:65 and 66, or SEQ ID NO:67 and 68, or SEQ ID NO:69 and 70, or SEQ ID NO:71 and 72, or SEQ ID NO:73 and 74, or SEQ ID NO:75 and 76, or SEQ ID NO:77 and 78, or SEQ ID NO:79 and 80, or SEQ ID NO:81 and 82, or SEQ ID NO:83 and 842, or SEQ ID NO: 85 and 86, or SEQ ID NO: 87 and 88, or SEQ ID NO: 89 and 90, or SEQ ID NO:91 and 92, or SEQ ID NO:93 and 94, or SEQ ID NO:95 and 96, or SEQ ID NO:97 and 98, or SEQ ID NO:99 and 100, or SEQ ID NO: 101 and 102, or SEQ ID NO: 103 and 104, or SEQ ID NO: 105 and 106, or SEQ ID NO: 107 and 108, or SEQ ID NO: 109 and 110, or SEQ ID NO: 111 and 112, or SEQ ID NO: 113 and 114, or SEQ ID NO: 115 and 116, or SEQ ID NO: 117 and 118, or SEQ ID NO: 119 and 120, or 61
SEQ ID NO: 121 and 122, or SEQ ID NO: 123 and 124, or SEQ ID NO: 125 and 126, or
SEQ ID NO: 127 and 128, or SEQ ID NO: 129 and 130, or SEQ ID NO: 131 and 132, or
SEQ ID NO: 133 and 134, or SEQ ID NO: 135 and 136, or SEQ ID NO: 137 and 138, or
SEQ ID NO: 139 and 140, or SEQ ID NO: 141 and 142, or SEQ ID NO: 143 and 144, or
SEQ ID NO: 145 and 146, or SEQ ID NO: 147 and 148, or SEQ ID NO: 149 and 150, or
SEQ ID NO: 151 and 152, or SEQ ID NO: 153 and 154, or SEQ ID NO: 155 and 156, or
SEQ ID NO: 157 and 158. The antibody against human Mac-1 according to claim 1, wherein the heavy-chain variable region sequence and the light-chain variable region sequence have the following sequence pair: SEQ ID NO: 129 and 130, or SEQ ID NO: 131 and 132, or SEQ ID NO: 133 and 134, or SEQ ID NO:71 and 72, or SEQ ID NO: 11 and 12. A pharmaceutical composition for treating a disease or disorder associated with acute and chronic inflammation or a cancer, wherein the pharmaceutical composition comprises the antibody according to any one of claims 1-8 and a pharmaceutically acceptable carrier or excipient. A method for treating a disease or disorder associated with acute and chronic inflammation or a cancer, comprising: administering to a subject in need thereof an effective amount of the antibody according to any one of claims 1-8.
PCT/US2021/065802 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and uses thereof Ceased WO2022147338A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202180094281.XA CN116963772A (en) 2020-12-30 2021-12-30 Monoclonal antibodies against human MAC-1 and their uses
JP2023540621A JP2024501884A (en) 2020-12-30 2021-12-30 Monoclonal antibody against human MAC-1 and its use
BR112023013052A BR112023013052A2 (en) 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and its uses
CA3203552A CA3203552A1 (en) 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and uses thereof
EP21916546.1A EP4271413A4 (en) 2020-12-30 2021-12-30 MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
US18/259,958 US20240084017A1 (en) 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and uses thereof
AU2021413899A AU2021413899A1 (en) 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and uses thereof
KR1020237025748A KR20230140448A (en) 2020-12-30 2021-12-30 Monoclonal antibody against human Mac-1 and uses thereof
TW111119536A TWI869677B (en) 2020-12-30 2022-05-25 Monoclonal antibody against human mac-1 and uses thereof
TW113121565A TWI911761B (en) 2020-12-30 2022-05-25 Monoclonal antibody against human mac-1 and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063131893P 2020-12-30 2020-12-30
US63/131,893 2020-12-30

Publications (1)

Publication Number Publication Date
WO2022147338A1 true WO2022147338A1 (en) 2022-07-07

Family

ID=82259686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/065802 Ceased WO2022147338A1 (en) 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and uses thereof

Country Status (10)

Country Link
US (1) US20240084017A1 (en)
EP (1) EP4271413A4 (en)
JP (1) JP2024501884A (en)
KR (1) KR20230140448A (en)
CN (1) CN116963772A (en)
AU (1) AU2021413899A1 (en)
BR (1) BR112023013052A2 (en)
CA (1) CA3203552A1 (en)
TW (2) TWI911761B (en)
WO (1) WO2022147338A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240002515A1 (en) * 2015-06-12 2024-01-04 Ascendo Biotechnology, Inc. Methods and antibodies for modulation of immunoresponse
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140147445A1 (en) * 2010-10-21 2014-05-29 Baker Idi Heart & Diabetes Institute Holdings Ltd. Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis
US20160108110A1 (en) * 2014-08-07 2016-04-21 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US20160130326A1 (en) * 2013-06-26 2016-05-12 Numab Ag Novel antibody frameworks

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1254289A1 (en) * 2015-06-12 2019-07-19 台湾基督长老教会马偕医疗财团法人马偕纪念医院 Methods and antibodies for modulation of immunoresponse
RU2020118134A (en) * 2017-11-03 2021-12-03 Маккей Мемориал Хоспитал METHOD FOR MODULATION OF TUMOR ASSOCIATED MYELOID CELLS AND IMPROVEMENT OF BLOCKADE OF IMMUNE CONTROL POINTS
TWI911144B (en) * 2018-08-09 2026-01-11 英屬開曼群島商先知生物科技股份有限公司 Method for suppression of hepapitis b virus replication and hepapitis b virus surface antigen secretion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140147445A1 (en) * 2010-10-21 2014-05-29 Baker Idi Heart & Diabetes Institute Holdings Ltd. Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis
US20160130326A1 (en) * 2013-06-26 2016-05-12 Numab Ag Novel antibody frameworks
US20160108110A1 (en) * 2014-08-07 2016-04-21 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4271413A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240002515A1 (en) * 2015-06-12 2024-01-04 Ascendo Biotechnology, Inc. Methods and antibodies for modulation of immunoresponse
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Also Published As

Publication number Publication date
US20240084017A1 (en) 2024-03-14
EP4271413A1 (en) 2023-11-08
TW202438108A (en) 2024-10-01
TWI869677B (en) 2025-01-11
TW202325340A (en) 2023-07-01
AU2021413899A1 (en) 2023-08-03
CN116963772A (en) 2023-10-27
BR112023013052A2 (en) 2023-09-26
KR20230140448A (en) 2023-10-06
AU2021413899A9 (en) 2025-03-13
TWI911761B (en) 2026-01-11
EP4271413A4 (en) 2025-07-30
JP2024501884A (en) 2024-01-16
CA3203552A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
TWI869677B (en) Monoclonal antibody against human mac-1 and uses thereof
JP2021050225A (en) Methods for expanding or depleting t regulatory cells
JP2022513685A (en) Methods for Treatment with Adoptive Cell Therapy
EP3721901A1 (en) Toxicity management for anti-tumor activity of cars
US20240060046A1 (en) Expanded and stimulated natural killer cells
WO2018229163A1 (en) Methods of activating v delta 2 negative gamma delta t cells
EP3515475B1 (en) Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
WO2021095010A1 (en) Renal cell carcinoma (rcc) therapy using genetically engineered t cells targeting cd70
TWI913728B (en) Chimeric antigen receptor t cell therapy
US20260048084A1 (en) Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)
US20220378829A1 (en) Genetically engineered immune cells targeting cd70 for use in treating solid tumors
WO2021155830A1 (en) Anti-hpv t cell receptors and engineered cells
WO2022127401A1 (en) Chimeric antigen receptor targeting cd123 and use thereof
Pillarisetti et al. Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models
JP2023024996A (en) Chimeric antigen receptor T cell therapy
EP4479743A1 (en) Predicting adverse events from immunotherapy
WO2022098756A1 (en) Chimeric antigen receptor cell therapy
TWI825131B (en) Treatment or preventive agents for HTLV-1 associated myelopathy (HAM), and treatment methods for HAM
Huang et al. Efficacy-enhanced and cytokine release syndrome-attenuated anti-CD7 universal chimeric antigen receptor-T cell therapy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
US20250290154A1 (en) Predictive markers for immunotherapy
EP4568999A1 (en) Chimeric antigen receptor domains
CN116510010A (en) anti-PD-1 antibodies and their use in the preparation of a medicament for treating non-small cell lung cancer patients
WO2026096859A2 (en) Biomarkers related to immunotherapy efficacy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21916546

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3203552

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18259958

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2023540621

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023013052

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021413899

Country of ref document: AU

Date of ref document: 20211230

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021916546

Country of ref document: EP

Effective date: 20230731

WWE Wipo information: entry into national phase

Ref document number: 202180094281.X

Country of ref document: CN

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023013052

Country of ref document: BR

Free format text: COM BASE NA PORTARIA/INPI/NO 48/2022, APRESENTE NOVO CONTEUDO DE LISTAGEM POIS O CONTEUDO DA LISTAGEM APRESENTADA NA PETICAO NO 870230056214 DE 28/06/2023 POSSUI OS CAMPOS 110 DIVERGENTES DO PEDIDO EM QUESTAO. A EXIGENCIA DEVE SER RESPONDIDA, COM A INCLUSAO DO CAMPO 140 , EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112023013052

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230628